Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020230142 - CANCER TREATMENT

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

CLAIMS

1. A superantigen covalently linked to a targeting moiety that binds a cancer antigen

expressed by cancerous cells within the subject for (i) reducing the likelihood of a recurrence of a cancer in a subject, (ii) delaying reoccurrence of a cancer in a subject or (iii) promoting anticancer immune memory and/or epitope spreading in a subject.

2. A superantigen conjugate comprising a superantigen covalently linked to a targeting

moiety that binds a cancer antigen expressed by cancerous cells within the subject for inducing at least a first and second epitope-specific immune response in a subject with cancer, wherein the first epitope-specific immune response is directed to the cancer antigen through the superantigen conjugate and the second epitope-specific immune response is not directed to the cancer antigen or the superantigen and is mediated by epitope spreading.

3. A superantigen conjugate comprising a superantigen covalently linked to a targeting

moiety that binds a single type of cancer antigen expressed by cancerous cells within the subject for mediating a long term (at least 6 months, 7 months, 8 month, 9 months, 10 months, 11 months, 1 year, 2 years or more) immune response against multiple, different cancer antigens expressed by a cancerous cell in a subject in need of treatment.

4. The superantigen of any one of claims 1-3 for use in combination with an

immunopotentiator.

5. The superantigen of any one of claims 1-4, wherein the cancer is a 5T4-expressing cancer.

6. The superantigen of any one of claims 1-5, wherein the cancer is selected from breast cancer, bladder cancer, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, liver cancer, melanoma, mesothelioma, non small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, and skin cancer.

7. The superantigen of claim 6, wherein the cancer is colon or colorectal cancer.

8. A superantigen conjugate comprising a superantigen covalently linked to a targeting

moiety that binds the cancer antigen for stimulating an immune response in a subject against a cancerous cell which does not express a cancer antigen.

9. The superantigen of claim 8, for use in combination with an immunopotentiator.

10. The superantigen of claim 9, wherein the cancerous cell is selected from a breast cancer, bladder cancer, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, liver cancer, melanoma, mesothelioma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, and skin cancer cell.

11. The superantigen of claim 10, wherein the cancerous cell is a colon or colorectal cancer cell.

12. The superantigen of any one of claims 1-11, wherein the cancer antigen is selected from EpCAM and 5T4.

13. The superantigen of claim 12, wherein the cancer antigen is 5T4.

14. The superantigen of any one of claims 1-13, wherein the immunopotentiator is a PD-1 based inhibitor.

15. The superantigen of claim 14, wherein the PD-1 based inhibitor is a PD-1 or PD-L1 inhibitor.

16. The superantigen of any one of claims 1-15, wherein the subject has previously received a different anti-cancer therapy.

17. The superantigen of claim 16, wherein the cancer is refractory to the anti-cancer therapy.

18. The superantigen of claim 17, wherein the cancer recurred following the anti-cancer therapy

19. The superantigen of any one of claims 16-18, wherein the anti-cancer therapy comprises a chimeric antigen receptor (CAR) T-cell or a bispecific T-cell engager (BiTE).

20. The superantigen of any one of claims 1-19, wherein the superantigen conjugate is

administered to the subject before, at the same time as, or after the PD-1 or PD-L1 inhibitor.

21. The superantigen of any one of claims 1-20, wherein the superantigen comprises

Staphylococcal enterotoxin A or an immunologically variant and/or fragment thereof.

22. The superantigen of any one of claims 1-21, wherein the superantigen comprises the

amino acid sequence of SEQ ID NO: 3, or an immunologically reactive variant and/or fragment thereof.

23. The superantigen of any one of claims 1-22, wherein the targeting moiety is an antibody.

24. The superantigen of claim 23 wherein the antibody is an anti-5T4 antibody.

25. The method of claim 24, wherein the anti-5T4 antibody comprises a Fab fragment that binds a 5T4 cancer antigen.

26. The superantigen of claim 25, wherein the anti-5T4 antibody comprises a heavy chain comprising amino acid residues 1-222 of SEQ ID NO: 8 and a light chain comprising amino acid residues 1-214 of SEQ ID NO: 9.

27. The superantigen of any one of claims 1-26, wherein the superantigen conjugate

comprises a first protein chain comprising SEQ ID NO: 8 and a second protein chain comprising SEQ ID NO: 9.

28. The superantigen of any one of claims 15-27, wherein the PD-1 inhibitor is an anti-PD-1 antibody.

29. The superantigen of claim 28, wherein the anti-PD-1 antibody is selected from nivolumab pembrolizumab, and cemiplimab.

30. The superantigen of any one of claims 15-29, wherein the PD-L1 inhibitor is an anti-PD- L1 antibody.

31. The superantigen of claim 30, wherein the anti-PD-Ll antibody is selected from

atezolizumab, avelumab, and durvalumab.